The Working Paper sheds light on the extent to which “value” is considered in pricing and/or coverage decisions in 14 OECD member countries. It describes methods used by countries to assess the therapeutic benefits of new products, as well as approaches for economic evaluation, where relevant, and aims to illustrate how value is assessed and what is its impact on pricing and/or reimbursement decisions.
Dementia is a devastating condition for the people affected, their family and friends, and for health systems. Through its global reach and ability to bring together government and non-government perspectives, OECD is in a unique position to face up to the challenge.
The large and growing human and financial cost of dementia provides an imperative for policy action. It is already the second largest cause of disability for the over-70s and it costs $645bn per year globally, and ageing populations mean that these costs will grow.
There is no cure or effective treatment for dementia, and too often people do not get appropriate health and care services, leading to a poor quality of life. Our failure to tackle these issues provides a compelling illustration of some of today’s most pressing policy challenges. We need to rethink our research an innovation model, since progress on dementia has stalled and investment is just a fraction of what it is for other diseases of similar importance and profile. But even then a cure will be decades away, so we need better policies to improve the lives of people living with dementia now. Communities need to adjust to become more accommodating of people with dementia and families who provide informal care must be better supported. Formal care services and care institutions need to promote dignity and independence, while coordination of health and care services must be improved. But there is hope: if we can harness big data we may be able to address the gaps in our knowledge around treatment and care.
OECD countries are developing strategies to improve the quality of life of those affected by dementia and to support long-term efforts for a disease-modifying therapy or cure. The OECD jointly hosted an international workshop in Toronto with the Ontario Brain Institute (OBI) and the Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto on 14-15 September 2014. The aim of the workshop was to advance international discussion of the opportunities and challenges, as well as successful strategies, for sharing and linking the massive amounts of population-based health and health care data that are routinely collected (broad data) with detailed clinical and biological data (deep data) to create an international resource for research, planning, policy development, and performance improvement. The workshop brought together leading researchers and academics, industry and non-government experts to provide new insights into the opportunities and challenges in making “broad and deep” data a reality – from funding to data standards, to data sharing, to new analytics, to protecting privacy, and to engaging with stakeholders and the public. Government leadership and public-private partnership will be needed to create and sustain big data resources, including financing for data infrastructure and incentives for data sharing.
Health workers are crucial for ensuring access to high quality and cost-effective care. Current projects analyse different aspects of health workforce policy, including how countries can improve their health workforce planning, what policymakers can do to ensure that doctors practice where they are most needed, and whether health workers put their skills to effective use in their jobs.
Over the past decade, many OECD countries have introduced new policies to tackle excessive waiting times for elective treatments with some success. However, in the wake of the recent economic downturn and severe pressures on public budgets, waiting times may rise again, and it is important to understand which policies work.
Italy has significantly improved the quality of health care in recent decades but needs to tackle the wide disparities that remain between regions, according to a new OECD report.
Despite remarkable progress in health status and life expectancy in OECD countries over the past decades, there remain large inequalities not only across countries, but also across population groups within each country. These inequalities in health status are linked to many factors, including differences in exposure to risk factors to health and in access to health care.
How health providers are paid is one of the key policy levers that countries have to drive health system performance. The 2012 HSC Survey analyses the payment modes currently in use in OECD countries to remunerate primary care, outpatient specialist care and inpatient care, the price regulations for health services and identifies new innovative modes of payments in more detail.
English, PDF, 306kb
Excellent population health status and good outcomes associated with acute care reflect a high-performing health system in Norway. Norway’s good health system comes at a cost – Norway’s per capita health expenditure is the highest in Europe.